World Health Organization Issues Warning Over Acute Lack of Weight-Loss Jabs

Less than 10% of individuals that would benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the drugs.

Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The new guidelines recognises that obesity is a long-term condition that can be addressed with holistic and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the treatments that can assist patients in reducing significant weight, explains the organization.

GLP-1 Therapy Shortage

Despite the current best projected case, the supply of these medications might only reach about 100 million people – under 10% of the global need, according to the WHO.

The recommendation urges nations and manufacturers to expand access, through approaches like licensing agreements.

The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.

How Obesity Drugs Function

The injections replicate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake.

People commonly start to lose weight after several weeks of beginning the weekly injections.

Research suggests patients may regain a significant portion within a year of stopping the treatment, because their typical hunger resume.

To be overweight or obese raises your chance for developing health problems, including type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity concerns people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the WHO.